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Objectives The aim of this study was to examine rapid-rate nonsustained ventricular tachycardia (RR-NSVT) during routine im-
plantable cardioverter-defibrillator (ICD) evaluation in patients with heart failure and its relationship to outcomes.
Background The clinical implications of RR-NSVT identified during routine ICD interrogation are unclear. In this study, the oc-
currence of RR-NSVT and its association with ICD shocks and mortality in SCD-HeFT (Sudden Cardiac Death in
Heart Failure Trial) were examined.
Methods The 811 patients who received ICDs in SCD-HeFT constituted the study population. The occurrence of RR-NSVT
and its association with ICD shocks and mortality in SCD-HeFT were examined.
Results RR-NSVT was documented on ICD interrogation in 186 of 811 patients (22.9%). The mean duration of RR-NSVT
was 26.4  9.1 beats (7.5  2.6 s), with a mean cycle length of 259  32 ms. Polymorphic RR-NSVT ac-
counted for 56% of episodes. Compared with patients without RR-NSVT, those with RR-NSVT were less likely to
be taking beta-blockers, statins, or aspirin at enrollment. After adjusting for other known predictors of mortality
in SCD-HeFT, RR-NSVT was independently associated with appropriate ICD shocks (hazard ratio: 4.25; 95% confi-
dence interval: 2.94 to 6.14; p  0.0001), with all-cause mortality (hazard ratio: 2.40; 95% confidence interval:
1.62 to 3.54; p  0.0001), and with a composite of all-cause mortality and appropriate ICD shocks (hazard ra-
tio: 3.03; 95% confidence interval: 2.21 to 4.15; p  0.0001).
Conclusions RR-NSVT identified on routine ICD interrogation should be considered an important clinical event. RR-NSVT during ICD
interrogation is associated with appropriate ICD shocks and all-cause mortality. The clinical evaluation of patients with
RR-NSVT should include intensification of medical therapy, particularly beta-blockers, or other appropriate clinical in-
terventions. (Sudden Cardiac Death in Heart Failure Trial [SCD-HeFT]; NCT00000609) (J Am Coll Cardiol 2013;61:
2161–8) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.02.046Patients with implantable cardioverter-defibrillators (ICDs)
are followed by both electrophysiologists and implanting
cardiologists, often in nurse-directed device clinics or via
remote monitoring. Current device interrogations contain
an increasingly large amount of data that require review
beyond those rhythms that trigger ICD therapy. The
significance of identifying rapid-rate nonsustained ventric-
ular tachycardia (RR-NSVT) may be unclear.
From the *University of Washington, Seattle, Washington; †Seattle Institute for
Cardiac Research, Seattle, Washington; and the ‡Duke University Clinical Research
Institute, Durham, North Carolina. This study was supported by grants U01
HL55766, U01 HL55297, and U01 HL55496 from the National Heart, Lung, and
Blood Institute and by Medtronic. Ms. Anderson is a consultant for Boston Scientific
Corporation. Dr. Mark has received research funding from Eli Lilly & Company,
Medtronic, Gilead, and AstraZeneca. Dr. Lee performs limited consulting for
Medtronic. Dr. Bardy has received research funding from St. Jude Medical, is a
consultant for and board member of Cameron Health Corporation and has equity andSome studies have shown that nonsustained ventricular
tachycardia (NSVT) increases mortality (1–3), while others
have shown that it has no additional effect on mortality
(4,5). These studies have generally used the occurrence of
NSVT on ambulatory outpatient monitoring for analysis.
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Implications of NSVT in ICD Heart Failure Patients May 28, 2013:2161–8ICD therapy but terminates before
the delivery of ICD therapy may
well have different significance
than short NSVT episodes iden-
tified on outpatient ambulatory
monitoring. The purpose of this
study was to examine the fre-
quency and characteristics of
RR-NSVT detected during ICD
interrogation in patients with
moderate heart failure (HF) and
assess its association with appro-
priate shocks and mortality.
Methods
The study design, subject demo-
graphics, and main study out-
comes of SCD-HeFT (Sudden
Cardiac Death in Heart Failure Trial) have been reported
previously (6,7). SCD-HeFT randomized 2,521 subjects in
equal proportions to receive single-lead ICDs, amiodarone, or
placebo. The median duration of follow-up was 45.5 months.
Of the 829 patients randomized to receive ICDs, 17 refused
the ICDs after randomization and 1 patient died before
receiving the device. Therefore, 811 patients actually re-
ceived ICDs. Among the 811 patients who received ICDs,
there were 163 deaths, 42 among patients with RR-NSVT
and 121 among those without RR-NSVT. Subjects enrolled
in SCD-HeFT were at least 18 years of age, had chronic
stable New York Heart Association class II or III HF for at
least 3 months due to ischemic or nonischemic causes, had
left ventricular ejection fraction35%, and were on optimal
HF medical therapy. Subjects were enrolled from Septem-
ber 16, 1997, to July 18, 2001, with follow-up continuing
through October 31, 2003. Vital status was available for
100% of subjects at the end of the follow-up period.
SCD-HeFT was approved by the institutional review com-
mittee at each participating site, and all subjects provided
written informed consent.
The ICDs implanted in SCD-HeFT were single-lead
devices (model 7223; Medtronic, Inc., Minneapolis, Min-
nesota) because there were no pre-trial indications for
pacemaker therapy in the SCD-HeFT population. The
maximal device output was 30 J for a total of 6 shocks per
detected tachyarrhythmia episode.
SCD-HeFT included a pre-specified protocol for ICD
programming. This included a single zone of therapy at a
detection rate of 188 beats/min. The initial detection
interval was for 18 of 24 beats, and the redetect interval was
for 12 of 16 beats. RR-NSVT for which electrograms would
be available were those that also met the detection criteria
for ICD shock delivery but terminated before shock delivery
or “abortion” of shock delivery. The SCD-HeFT protocol
Abbreviations
and Acronyms
ATP  antitachycardia
pacing
CI  confidence interval
HF  heart failure
HR  hazard ratio
ICD  implantable
cardioverter-defibrillator
NSVT  nonsustained
ventricular tachycardia
RR-NSVT  rapid-rate
nonsustained ventricular
tachycardia
VF  ventricular fibrillation
VT  ventricular
tachycardiafor therapy programming was shock-only mode. No anti- mtachycardia pacing (ATP) was included in the implantation
protocol, because the use of ATP was not considered
routine for patients without known histories of ventricular
tachycardia (VT) at the time the study was conducted.
Pre-shock electrogram storage allowed for approximately 10
seconds of data. Post-shock electrograms stored up to 9
beats. The SCD-HeFT protocol for antibradycardia pacing
was set to 50 beats/min with hysteresis of 34 beats/min, the
minimal allowable rate.
All episodes of RR-NSVT meeting ICD detection cri-
teria were reviewed by the SCD-HeFT ICD core laboratory
and examined for morphology, ventricular origin confirma-
tion, and cycle length. The arrhythmia confirmation algo-
rithm in the Medtronic model 7223 would deliver a shock
if any 2 of the 4 intervals after charge end were 60 ms over
the fibrillation detection interval of 320 ms (380 ms).
Thus, the VT could have terminated, but for instance, a
single premature ventricular contraction after charge end
could cause an ICD shock to be delivered.
Sponsorship and oversight of SCD-HeFT were provided
by the National Heart, Lung, and Blood Institute. ICDs
were contributed to the study by the manufacturer
(Medtronic, Inc.). The authors had full access to the data
and take responsibility for its integrity. All authors have read
and agree to the manuscript as written.
Definitions. RR-NSVT was defined as any rhythm iden-
tified in the ICD log that met the ICD programmed
detection criteria but self-terminated. Over the 5 years of
the study, individual investigators occasionally implemented
programming changes and, therefore, NSVT detected at
shorter or longer detection integer counts or lower rates
than the protocol-determined criteria (at least 18 beats in
duration and at least 188 beats/min) were included in this
analysis, if electrograms were available for review to deter-
mine a ventricular origin. The determination of polymor-
phic versus monomorphic depended on an assessment of
QRS configuration consistency and cycle length variability
on review by the investigators. If QRS configuration was
variable from beat to beat and/or across the extent of the
rhythm, coupled with a variable cycle length (generally 40
s), the entire episode was considered polymorphic. A
onomorphic episode was identified if the QRS configu-
ation was identical or nearly so for all QRS complexes, with
enerally40-ms variability in cycle length across the entire
pisode and QRS configuration distinct from the baseline
hythm QRS configuration.
tatistical analysis. Baseline clinical characteristics are
ummarized using medians with 25th and 75th percentiles
or continuous variables and frequencies and percents for
ategorical variables. Group comparisons with respect to
hese characteristics were performed using likelihood ratio
hi-square tests for categorical variables and Wilcoxon rank
um tests for continuous variables. The associations of
R-NSVT with the end points of: 1) appropriate shock
i.e., shock for VT or ventricular fibrillation [VF]); 2) total
ortality; and 3) the composite of death or appropriate
c episo
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May 28, 2013:2161–8 Implications of NSVT in ICD Heart Failure Patientsshock were examined using Cox proportional hazards mod-
els in which the first occurrence of RR-NSVT during the
follow-up period was considered as a time-dependent cova-
riate. In the appropriate shock and composite models, the
first appropriate shock was credited to the RR-NSVT group
only if it occurred after the first episode of RR-NSVT.
Thus, these models specifically addressed the question of
whether RR-NSVT is associated with subsequent first
appropriate shock (i.e., appropriate shock among patients
who had not yet experienced one at the time of their
RR-NSVT episode). Cox models were adjusted for base-
line prognostic factors identified in the full SCD-HeFT
cohort to examine the added prognostic value (if any) of
RR-NSVT beyond that of baseline clinical factors. The
Figure 1 A Representative Example of Polymorphic Nonsustain
An implantable cardioverter-defibrillator electrogram demonstrating polymorphic no
Characteristics of RR-NSVT (n  681)Table 1 Characteristics of RR-NSVT (n  68
Characteristic
Duration of RR-NSVT episodes (number of beats)
Duration of RR-NSVT episodes (seconds)
Cycle length (ms) of all RR-NSVT episodes (n  681)
Cycle length (ms) of all monomorphic RR-NSVT (n  300)
Cycle length (ms) of all polymorphic RR-NSVT (n  381)
The difference in cycle length between monomorphic and polymorphi
RR-NSVT  rapid-rate nonsustained ventricular tachycardia.adjustment variables included age, sex, cause of HF, New
York Heart Association class, time since HF diagnosis,
left ventricular ejection fraction, distance covered on
6-minute walk, systolic blood pressure, diabetes, use of
angiotensin-converting enzyme inhibitors, use of
digoxin, use of beta-blockers, mitral regurgitation, renal
insufficiency, substance abuse, baseline electrocardio-
graphic intervals, and score on the Duke Activity Status
Index (8,9).
Risk relationships are expressed as hazard ratios (HRs)
with associated 95% confidence intervals (CIs) derived from
the Cox models. A p value 0.05 was considered statisti-
cally significant. All analyses were performed using SAS
version 8.2 (SAS Institute Inc., Cary, North Carolina).
ntricular Tachycardia
ined ventricular tachycardia.
n  SD Median (25th, 75th Percentile) Range
4 9.1 24 (20, 31) 12–51
5 2.6 7 (6, 10) 5–20
9 32 260 (240, 280) 180–350
3 21 270 (260, 290) 230–350
3 31 260 (210, 270) 180–310
des was statistically significant (p  0.0001).ed Ve
nsusta1)
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Frequency and characteristics of RR-NSVT. A total of
681 episodes of RR-NSVT were documented in 186 of the
811 patients who received ICDs (22.9%). The mean length
of RR-NSVT was 26.4  9.1 beats (7.5  2.6 s) (Table 1).
f the 681 episodes, 381 (56%) were considered polymor-
hic and 300 (44%) were identified to be monomorphic
Figs. 1 and 2). The mean cycle length was 259  32 ms.
olymorphic RR-NSVT had a shorter cycle length (243 
1 ms) compared with monomorphic RR-NSVT (273 
1 ms) (p  0.0001). If only the final 8 beats of an
RR-NSVT episode are considered, 38% of episodes were
polymorphic, and 62% were monomorphic; that is, many
episodes “stabilized” to monomorphic VT by the time of
the final 8 beats.
Fifty-four of the 681 episodes (7.9%) received ICD
shocks despite self-termination of the RR-NSVT. These
shocks were considered inappropriate and occurred in 38 of
the 186 patients (20.4%) who experienced 1 or more
episodes of RR-NSVT (Fig. 3). Thus, in total, 4.7% of the
811 patients who received ICDs in SCD-HeFT received
inappropriate shocks for RR-NSVT, or 0.94% per year
during the SCD-HeFT follow-up period.
Figure 2 A Representative Example of Monomorphic Nonsustai
An implantable cardioverter-defibrillator electrogram demonstrating monomorphic nClinical characteristics. The baseline clinical characteris-
tics of ICD patients who experienced 1 episode of
RR-NSVT during the trial are compared with the charac-
teristics of those patients who did not experience any
RR-NSVT in Table 2. Significant differences in patients
with RR-NSVT compared with those without RR-NSVT
included younger age, a higher percentage of men, lower
ejection fractions, higher heart rates, more nonischemic
causes of HF, less diabetes, and less hyperlipidemia. At
baseline, patients with RR-NSVT were significantly more
likely to be on an angiotensin-converting enzyme inhibitors
or angiotensin receptor blockers but less likely to be on
beta-blockers, statins, or aspirin compared with those with-
out RR-NSVT.
RR-NSVT and appropriate ICD shocks. Of the 811
patients with ICDs, 182 patients had 1 or more appropriate
ICD shocks for VT or VF with SCD-HeFT protocol pro-
gramming. Eighty-six of the 182 patients (47.3%) also had 1 or
more episodes of RR-NSVT. The time course of first RR-
NSVT or first appropriate shock was variable, with 46 of the
86 patients with RR-NSVT (53%) having at least 1 RR-
NSVT episode before any appropriate shock and 40 patients
(47%) having at least 1 appropriate shock before any RR-
NSVT. In a multivariable Cox model adjusted for independent
entricular Tachycardia
tained ventricular tachycardia.ned V
onsus
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associated with the risk for a subsequent first appropriate shock
(HR: 4.25; 95% CI: 2.94 to 6.14; p  0.0001) (Fig. 4).
Baseline clinical characteristics of the 86 patients with
RR-NSVT who also had appropriate shocks for VT or VF
were compared with those of the 100 patients with NSVT
who never had appropriate shocks for VT or VF over the
course of the study. Patients with RR-NSVT and appro-
priate shocks were older (p  0.018) and less likely to be on
beta-blockers (p  0.040) compared with those without
appropriate shocks (Table 3).
RR-NSVT and all-cause mortality. In multivariable Cox
analyses adjusted for other independent predictors of mortality
identified in SCD-HeFT, RR-NSVT was associated with a
2-fold higher risk for death compared with patients without
RR-NSVT (HR: 2.40; 95% CI: 1.62 to 3.54; p 0.0001) and
a 3-fold risk for appropriate shock or death (HR: 3.03; 95%
CI: 2.21 to 4.15; p  0.0001) (Fig. 4).
Discussion
We performed the first study investigating the characteris-
tics and prognosis of RR-NSVT detected on routine ICD
interrogation in patients with moderate HF with primary
Figure 3 Nonsustained Ventricular Tachycardia Leading to an I
An implantable cardioverter-defibrillator (ICD) electrogram demonstrating nonsustainedprevention ICD therapy. The main result of this study isthat long runs of RR-NSVT discovered during routine ICD
interrogation are associated with subsequent appropriate
ICD shocks and an increase in mortality. Prior studies
examining the significance of NSVT have relied on Holter
ambulatory electrocardiographic monitoring or telemetric
monitoring and have included any NSVT regardless of rate
and duration (generally 10 beats) (1–5). Considerable
ambiguity regarding the significance of NSVT resulted from
these studies, with some showing that NSVT increases
mortality (1–3) and others showing that NSVT had no
effect on mortality in patients with cardiovascular disease
(4,5). Although the clinical implications of NSVT in
patients without ICDs have shown conflicting outcomes
(1–5), this study has provided new information regarding
RR-NSVT identified during routine interrogation of ICDs.
Our study is unique, as the NSVT we studied was that
found on routine ICD interrogation meeting criteria to
potentially trigger ICD therapy. One advantage of our study
is the recording capabilities of an ICD. In contrast, previous
studies looking at the prognostic implications of NSVT did
so using only Holter monitors or hospital telemetric mon-
itoring (1–5) and thus recorded patients’ heart rhythms only
for brief periods of time, unlike an ICD, which continuously
ropriate Shock
cular tachycardia that self-terminates and is followed by an inappropriate ICD shock.napp
ventrirecords rhythms above the programmed VT or VF rate
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creased use of remote ICD monitoring, where the finding of
RR-NSVT might be ignored if ICD therapy was not
delivered. However, our results suggest that RR-NSVT
discovered during routine ICD interrogation should be
considered an important clinical event, similar to sustained
VT or VF requiring an ICD shock.
It is not surprising that we also identified an association
of RR-NSVT occurrence with an increased likelihood of an
appropriate shock for VT or VF; however, the temporal
relationship between RR-NSVT and sustained VT or VF
was variable. RR-NSVT preceded the first occurrence of
sustained VT or VF in only about half of the patients who
experienced both events. Previous studies have shown that
in patients with HF with ICDs implanted for primary
prevention, ICD shocks are associated with higher mortality
(9,10). Approximately 50% of patients with appropriate
ICD shocks also had RR-NSVT. Because of the variable
relationship of the occurrence of RR-NSVT and sustained
VT or VF triggering appropriate shocks, and the variable
time relationship between the occurrence of the 2 rhythms
in patients who experienced both, the ability to separate the
Baseline Clinical Characteristics forP ti nts With RR-NSVT V sus No RR-NSVTTable 2 Baseline Clinical Characteristics forPatients With RR-NSVT Versus No RR-NSVT
Baseline Characteristic
RR-NSVT
(n  186)
No RR-NSVT
(n  625)
p
Value*
Age (yrs) 58 (50, 67) 61 (53, 70) 0.024
Women 17% (31) 25% (154) 0.020
Nonwhite race 27% (51) 21% (132) 0.076
Weight (lb) 192 (165, 226) 189 (162, 217) 0.14
NYHA functional class III 35% (66) 31% (191) 0.21
Ischemic HF etiology 40% (74) 55% (346) 0.001
Ejection fraction (%) 20 (18, 26) 25 (20, 30) 0.001
Diabetes 23% (42) 33% (205) 0.007
Pulmonary disease 22% (40) 21% (131) 0.87
Hyperlipidemia 42% (78) 55% (343) 0.002
Hypertension 56% (104) 54% (337) 0.63
Atrial fibrillation/flutter 18% (33) 17% (106) 0.80
Syncope 8% (15) 6% (37) 0.31
QRS duration 120 ms 41% (77) 41% (259) 0.99
Systolic blood pressure
(mm Hg)
118 (106, 132) 118 (104, 130) 0.49
Diastolic blood pressure
(mm Hg)
70 (62, 80) 70 (60, 80) 0.91
Heart rate (beats/min) 76 (68, 88) 73 (64, 84) 0.008
Serum sodium (mEq/l) 139 (137, 141) 139 (137, 141) 0.52
Serum creatinine (mg/dl) 1.10 (0.90, 1.30) 1.10 (1.00, 1.40) 0.34
ACE inhibitors or ARBs 98% (182) 93% (584) 0.011
Beta-blockers 59% (110) 73% (455) 0.001
Digoxin 72% (133) 66% (411) 0.14
Aspirin 51% (95) 60% (372) 0.041
Statins 26% (49) 41% (256) 0.001
Aldosterone antagonist 15% (27) 20% (126) 0.076
Values aremedian (25th, 75th percentile) or % (n). *Likelihood ratio chi-square tests for categorical
variables and Wilcoxon rank sum tests for continuous variables.
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; HF  heart failure;
YHA  New York Heart Association; RR-NSVT  rapid-rate nonsustained ventricular tachycardia.mortality risks of RR-NSVT and rhythms lasting long tenough to result in an appropriate shock was not possible in
this analysis.
Another important finding is that RR-NSVT was fre-
quently identified (23% of the patients with ICDs) and was
often polymorphic. The modestly long detection interval,
combined with a capacitor charge time of about 4 to 15 s,
depending on battery age and shock strength, allowed the
identification of many self-terminating VT episodes. If the
detection time or charge time had been faster, many otherwise
self-terminating VT events would have been treated and
categorized as “appropriate” shocks for VT or VF.
Similar observations regarding self-terminating VT have
previously been noted in an analysis of the Pacing Fast
Ventricular Tachycardia Reduces Shock Therapies (Pain-
FREE Rx II) trial, in which many more appropriate
ICD-treated VT episodes were identified in patients ran-
domized to receive ATP therapy first (a therapy that will be
delivered sooner than shock therapy) compared with those
randomized to receive only ICD shock therapy (11). In the
shock-only treatment arm, 34% of fast VT episodes terminated
Baseline Clinical Characteristics for PatientsWith RR-NSVT With Appropriate ICD Shocks VersusThose With RR-NSVT Wi hou Appropriat ICD Shocks
Table 3
B seline Clinical Characteristics for Patients
With RR-NSVT With Appropriate ICD Shocks Versus
Those With RR-NSVT Without Appropriate ICD Shocks
Baseline Characteristic
RR-NSVT
With APP
(n  86)
RR-NSVT
Without APP
(n  100)
p
Value*
Age (yrs) 63 (51, 69) 56 (48, 65) 0.018
Women 15% (13) 18% (18) 0.60
Nonwhite race 23% (20) 31% (31) 0.24
Weight (lb) 192 (160, 221) 193 (167, 227) 0.55
NYHA functional class III 41% (35) 31% (31) 0.17
Ischemic HF etiology 47% (40) 34% (34) 0.082
Ejection fraction (%) 20 (18, 25) 22 (16, 30) 0.41
Diabetes 20% (17) 25% (25) 0.39
Pulmonary disease 24% (21) 19% (19) 0.37
Hyperlipidemia 43% (37) 41% (41) 0.78
Hypertension 51% (44) 60% (60) 0.23
Atrial fibrillation/flutter 19% (16) 17% (17) 0.78
NSVT (before enrollment) 38% (33) 29% (29) 0.18
Syncope 10% (9) 6% (6) 0.27
QRS duration 120 ms 43% (37) 40% (40) 0.68
Systolic blood pressure
(mm Hg)
120 (108, 132) 115 (106, 131) 0.38
Diastolic blood pressure
(mm Hg)
70 (63, 80) 70 (61, 79) 0.46
Heart rate (beats/min) 76 (68, 88) 76 (68, 88) 0.99
Serum sodium (mEq/l) 139 (137, 141) 139 (137, 141) 0.91
Serum creatinine (mg/dl) 1.10 (0.96, 1.30) 1.10 (0.90, 1.30) 0.84
ACE inhibitors or ARBs 97% (83) 99% (99) 0.24
Beta-blocker 51% (44) 66% (66) 0.040
Digoxin 76% (65) 68% (68) 0.25
Aspirin 53% (46) 49% (49) 0.54
Statins 26% (22) 27% (27) 0.83
Aldosterone antagonist 10% (9) 18% (18) 0.14
Values aremedian (25th, 75th percentile) or % (n). *Likelihood ratio chi-square tests for categorical
variables and Wilcoxon rank sum tests for continuous variables.
APP  appropriate ICD shock for ventricular tachycardia or ventricular fibrillation; ICD 
implantable cardiac defibrillator; NSVT  nonsustained ventricular tachycardia. Other abbrevia-
ions as in Table 2.
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TP interventions, although successful at terminating the VT,
ay in fact have been unneeded. A high rate of self-
erminating VT was also observed in MIRACLE-ICD (Mul-
icenter InSync ICD Randomized Clinical Evaluation), in
hich 48% of VF or VT episodes converted spontaneously
uring the ICD charge-up cycle (12).
The longer detection time used in SCD-HeFT was novel
or that era, and this factor, in addition to a single
igh–heart rate treatment zone (188 beats/min), may well
ave protected many patients from unnecessary shocks.
ore recently, the use of both longer detection times and
igher heart rate treatment zones has received widespread
cceptance on the basis of ICD programming strategy
tudies evaluating this question (13–15). Also, the improved
edetection confirmation algorithms of contemporary de-
ices will decrease the unneeded shocks for otherwise
elf-terminating VT. Thus, relatively long detection times
re an important factor in minimizing unneeded ICD
herapy, be it shocks or ATP, both of which could be
articularly detrimental in polymorphic VT.
A final interesting observation from our study was that
atients with RR-NSVT were less likely to be taking
eta-blockers or statins at enrollment into the trial than
atients without RR-NSVT. Recently, there are data to
uggest that statins may be associated with a decrease in
udden cardiac death in patients with HF (16,17). We
annot state from our data analysis whether the absence of
eta-blocker or statin therapy in these patients identifies a
reviously overlooked therapeutic opportunity or instead
erves as an indicator of a more ill patient population.
tudy limitations. For the majority of patients in this trial,
Event HR (95% CI)
A. Appropriate shock 4.25 (2.94, 6.14) <
B. All-cause mortality 2.40 (1.62, 3.54) <
C. Appropriate shock 3.03 (2.21, 4.15) <
or all-cause
mortality
Figure 4 Association of RR-NSVT With Appropriate Shocks for
and All-Cause Mortality
The association of RR-NSVT with A) the occurrence of appropriate implantable card
all-cause mortality. All outcomes are adjusted for baseline prognostic factors iden
tion functional class, time since the diagnosis of heart failure, left ventricular ejec
use of an ACE-inhibitor, use of digoxin, use of beta blocker, mitral regurgitation, re
and score on the Duke Activity Status Index8–9).
RR-NSVT  Rapid Rate Nonsustained VT; Appropriate shocks are those ICD shock
val; HR  hazard ratio; VT  ventricular tachycardia; VF  ventricular fibrillation.nly NSVT 188 beats/min (320 ms) that met theprogrammed detection criteria for the ICD could be iden-
tified in this study. Thus, only longer and faster episodes of
NSVT were documented. We therefore cannot state that
similar findings would have been observed with slower and
shorter episodes of NSVT. Additionally, the question of
whether RR-NSVT effect on mortality is independent of
appropriate shocks for longer episodes of VT or VF cannot
be clearly separated by this patient cohort and analysis.
Conclusions
The significant correlation between RR-NSVT identified
on ICD interrogation with both appropriate ICD shocks for
VT or VF and all-cause mortality should prompt physicians
to consider long runs of RR-NSVT as important clinical
events. Similar to patients with ICD shocks for VT and VF
who have been previously identified as being a higher risk
patient population (9,10), the clinical evaluation of patients
with RR-NSVT on ICD interrogation should be directed at
maximizing HF medical management and evaluating pa-
tients for remedial conditions, such as ischemia, or consid-
ering the need for additional advanced HF therapies.
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